We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 2

1.
Fig. 1.

Fig. 1. From: Metabolic Effects of a Growth Hormone-Releasing Factor in Obese Subjects with Reduced Growth Hormone Secretion: A Randomized Controlled Trial.

Enrollment and outcomes. FOBT, Fecal occult blood test.

Hideo Makimura, et al. J Clin Endocrinol Metab. 2012 December;97(12):4769-4779.
2.
Fig. 2.

Fig. 2. From: Metabolic Effects of a Growth Hormone-Releasing Factor in Obese Subjects with Reduced Growth Hormone Secretion: A Randomized Controlled Trial.

Effects of tesamorelin vs. placebo on IGF-I (A), abdominal VAT area (B), and cIMT (C). Panel A demonstrates the change in IGF-I from baseline over time in tesamorelin vs. placebo. Each point represents mean ± sem of IGF-I in each study group at baseline, 2 wk, and 1, 3, 6, 9, and 12 months. Although IGF-I levels at baseline were similar between the two groups (P = 0.17), IGF-I levels at all subsequent time points were significantly different between each group (P < 0.05 at each time point) with overall P < 0.0001 by longitudinal linear mixed-effects modeling. Panel B demonstrates the difference in VAT between treatment groups with tesamorelin demonstrating a net −19% improvement in VAT compared with placebo. Panel C demonstrates the differences in cIMT between treatment groups with tesamorelin demonstrating a net −6% improvement in cIMT compared with placebo. The T bars in B and C denote the se. Statistical significance was determined by longitudinal linear mixed-effects modeling with the last value carried forward for both B and C.

Hideo Makimura, et al. J Clin Endocrinol Metab. 2012 December;97(12):4769-4779.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk